Amgen (AMGN) Q1 'Disappointing' - Nomura
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- Wall St set for higher open as AI stocks rise, oil slides
Amgen (AMGN) Has the Best Pipeline in Biotech, Piper Jaffray Says
April 25, 2014 7:38 AM EDTPiper Jaffray analyst Joshua E. Schimmer, MD reiterated an Overweight rating and $143 price target on Amgen (NASDAQ: AMGN) Friday saying a deep dive analysis into AMGN's migraine program suggests they are likely to... More
Amgen, Inc. (AMGN) Misses Q1 EPS by 7c
April 22, 2014 4:48 PM EDTAmgen, Inc. (NASDAQ: AMGN) reported Q1 EPS of $1.87, $0.07 worse than the analyst estimate of $1.94. Revenue for the quarter came in at $4.52 billion versus the consensus estimate of $4.76 billion.
For earnings history and earnings-related data on Amgen, Inc. (AMGN) click here.
... More